{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:03:21Z","timestamp":1787771001880,"version":"build-2784847793"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"crossref","award":["IG-21614"],"award-info":[{"award-number":["IG-21614"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"crossref","award":["IG-21724"],"award-info":[{"award-number":["IG-21724"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"crossref","award":["IG-26039"],"award-info":[{"award-number":["IG-26039"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hum Genomics"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>CBL syndrome is a RASopathy caused by heterozygous germline mutations of the Casitas B-lineage lymphoma (CBL) gene. It is characterized by heterogeneous clinical phenotype, including developmental delay, facial dysmorphisms, cardiovascular malformations and an increased risk of cancer development, particularly juvenile myelomonocytic leukemia (JMML). Although the clinical phenotype has been progressively defined in recent years, immunological manifestations have not been well elucidated to date.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We studied the genetic, immunological, coagulative, and clinical profile of a family with CBL syndrome that came to our observation after the diagnosis of JMML, with homozygous CBL mutation, in one of the members.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Variant analysis revealed the co-occurrence of CBL heterozygous mutation (c.1141\u00a0T\u2009&gt;\u2009<jats:italic>C<\/jats:italic>) and<jats:italic>SH2B3<\/jats:italic>mutation (c.1697G\u2009&gt;\u2009<jats:italic>A<\/jats:italic>) in two other members. Patients carrying both mutations showed an ALPS-like phenotype characterized by lymphoproliferation, cytopenia, increased double-negative T-cells, impaired Fas-mediated lymphocyte apoptosis, altered cell death in PBMC and low TRECs expression. A coagulative work-up was also performed and showed the presence of subclinical coagulative alterations in patients carrying both mutations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In the reported family, we described immune dysregulation, as part of the clinical spectrum of CBL mutation with the co-occurrence of SH2B3.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s40246-022-00414-y","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T11:03:12Z","timestamp":1663585392000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Immune dysregulation associated with co-occurring germline CBL and SH2B3 variants"],"prefix":"10.1186","volume":"16","author":[{"given":"Francesco","family":"Baccelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Leardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Muratore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Messelodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore Nicola","family":"Bertuccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Chiriaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Cancrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Castagnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Pedace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pession","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayami","family":"Yoshimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Niemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Tartaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Masetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,19]]},"reference":[{"key":"414_CR1","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ajhg.2010.06.015","volume":"87","author":"S Martinelli","year":"2010","unstructured":"Martinelli S, De Luca A, Stellacci E, Rossi C, Checquolo S, Lepri F, et al. Heterozygous germline mutations in the CBL tumor-suppressor gene cause a noonan syndrome-like phenotype. Am J Hum Genet. 2010;87:250\u20137. https:\/\/doi.org\/10.1016\/j.ajhg.2010.06.015.","journal-title":"Am J Hum Genet"},{"key":"414_CR2","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/nrm1762","volume":"6","author":"MHH Schmidt","year":"2005","unstructured":"Schmidt MHH, Dikic I. The Cbl interactome and its functions. Nat Rev Mol Cell Biol. 2005;6:907\u201318.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"414_CR3","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/humu.22809","volume":"36","author":"S Martinelli","year":"2015","unstructured":"Martinelli S, Stellacci E, Pannone L, D\u2019Agostino D, Consoli F, Lissewski C, et al. Molecular diversity and associated phenotypic spectrum of germline CBL mutations. Hum Mutat. 2015;36:787\u201396.","journal-title":"Hum Mutat"},{"key":"414_CR4","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1136\/jmg.2010.076836","volume":"47","author":"B P\u00e9rez","year":"2010","unstructured":"P\u00e9rez B, Mechinaud F, Galambrun C, Ben Romdhane N, Isidor B, Philip N, et al. Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia. J Med Genet. 2010;47:686\u201391.","journal-title":"J Med Genet"},{"key":"414_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1749-6632.2010.05790.x","volume":"1214","author":"M Tartaglia","year":"2010","unstructured":"Tartaglia M, Gelb BD. Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. Ann NY Acad Sci. 2010;1214:99\u2013121.","journal-title":"Ann NY Acad Sci"},{"issue":"9","key":"414_CR6","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/ng.641","volume":"42","author":"CM Niemeyer","year":"2010","unstructured":"Niemeyer CM, Kang MW, Shin DH, Furlan I, Erlacher M, Bunin NJ, Bunda S, Finklestein JZ, Sakamoto KM, Gorr TA, Mehta P. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic Leukemia. Nat Genet. 2010;42(9):794\u2013800.","journal-title":"Nat Genet"},{"key":"414_CR7","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1182\/blood-2009-01-198416","volume":"114","author":"ML Loh","year":"2009","unstructured":"Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S, et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood. 2009;114:1859\u201363.","journal-title":"Blood"},{"key":"414_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2015.00037","author":"R Masetti","year":"2015","unstructured":"Masetti R, Vendemini F, Zama D, Biagi C, Pession A, Locatelli F. Acute myeloid leukemia in infants: biology and treatment. Front Pediatr. https:\/\/doi.org\/10.3389\/fped.2015.00037","journal-title":"Front Pediatr"},{"issue":"12","key":"414_CR9","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1038\/leu.2013.203","volume":"27","author":"M Strullu","year":"2013","unstructured":"Strullu M, Caye A, Cassinat B, Fenneteau O, Touzot F, Blauwblomme T, et al. In hematopoietic cells with a germline mutation of CBL, loss of heterozygosity is not a signature of juvenile myelo-monocytic leukemia. Leukemia. 2013;27(12):2404\u20137. https:\/\/doi.org\/10.1038\/leu.2013.203.","journal-title":"Leukemia"},{"key":"414_CR10","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/jmedgenet-2016-104432","volume":"54","author":"S Guey","year":"2017","unstructured":"Guey S, Grangeon L, Brunelle F, Bergametti F, Amiel J, Lyonnet S, et al. De novo mutations in CBL causing early-onset paediatric moyamoya angiopathy. J Med Genet. 2017;54:550\u20137.","journal-title":"J Med Genet"},{"key":"414_CR11","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1097\/MPH.0000000000001448","volume":"42","author":"L Cortellazzo Wiel","year":"2020","unstructured":"Cortellazzo Wiel L, Pastore S, Taddio A, Tommasini A. A case of uveitis in a patient with juvenile myelomonocytic leukemia successfully treated with adalimumab. J Pediatr Hematol Oncol. 2020;42:e373\u20136.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"414_CR12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/bjh.17234","volume":"192","author":"AM Ali","year":"2021","unstructured":"Ali AM, Cooper J, Walker A, Jones D, Saad A. Adult\u2010onset acute myeloid leukaemia in a patient with germline mutation of CBL. Br J Haematol. 2021;192(3):665\u20137. https:\/\/doi.org\/10.1111\/bjh.17234.","journal-title":"Br J Haematol"},{"issue":"14","key":"414_CR13","doi-asserted-by":"publisher","first-page":"10969","DOI":"10.1074\/jbc.M109.094920","volume":"285","author":"CBF Thien","year":"2010","unstructured":"Thien CBF, Dagger SA, Steer JH, Koentgen F, Jansen ES, Scott CL, et al. c-Cbl promotes T cell receptor-induced thymocyte apoptosis by activating the phosphatidylinositol 3-kinase\/Akt pathway. J Biol Chem. 2010;285(14):10969\u201381. https:\/\/doi.org\/10.1074\/jbc.M109.094920.","journal-title":"J Biol Chem"},{"key":"414_CR14","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.immuni.2007.03.015","volume":"26","author":"Y Kitaura","year":"2007","unstructured":"Kitaura Y, Jang IK, Wang Y, Han YC, Inazu T, Cadera EJ, et al. Control of the B cell-intrinsic tolerance programs by ubiquitin ligases Cbl and Cbl-b. Immunity. 2007;26:567\u201378.","journal-title":"Immunity"},{"key":"414_CR15","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/ni855","volume":"3","author":"M Naramura","year":"2002","unstructured":"Naramura M, Jang I-K, Kole H, Huang F, Haines D, Gu H. c-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation. Nat Immunol. 2002;3:1192\u20139.","journal-title":"Nat Immunol"},{"key":"414_CR16","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3390\/cells8050498","volume":"8","author":"CL Lyle","year":"2019","unstructured":"Lyle CL, Belghasem M, Chitalia VC. c-Cbl: an important regulator and a target in angiogenesis and tumorigenesis. Cells. 2019;8:498.","journal-title":"Cells"},{"issue":"1","key":"414_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/ph15010024","volume":"15","author":"R Morris","year":"2021","unstructured":"Morris R, Butler L, Perkins A, Kershaw NJ, Babon JJ. The role of LNK (SH2B3) in the regulation of JAK-STAT signalling in haematopoiesis. Pharmaceuticals (Basel). 2021;15(1):24.","journal-title":"Pharmaceuticals (Basel)"},{"key":"414_CR18","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.bcp.2011.06.023","volume":"82","author":"J Devallire","year":"2011","unstructured":"Devallire J, Charreau B. The adaptor Lnk (SH2B3): an emerging regulator in vascular cells and a link between immune and inflammatory signaling. Biochem Pharmacol. 2011;82:1391\u2013402.","journal-title":"Biochem Pharmacol"},{"key":"414_CR19","first-page":"1661","volume":"31","author":"N Maslah","year":"2017","unstructured":"Maslah N, Cassinat B, Verger E, Kiladjian JJ, Velazquez L. The role of LNK\/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders. Leukemia Nat Publish Group. 2017;31:1661\u201370.","journal-title":"Leukemia Nat Publish Group"},{"key":"414_CR20","doi-asserted-by":"publisher","first-page":"E231","DOI":"10.1002\/ajh.25552","volume":"94","author":"G Coltro","year":"2019","unstructured":"Coltro G, Lasho TL, Finke CM, Gangat N, Pardanani A, Tefferi A, et al. Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Am J Hematol. 2019;94:E231\u20134.","journal-title":"Am J Hematol"},{"key":"414_CR21","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1182\/blood-2013-05-500850","volume":"122","author":"A Perez-Garcia","year":"2013","unstructured":"Perez-Garcia A, Ambesi-Impiombato A, Hadler M, Rigo I, LeDuc CA, Kelly K, et al. Genetic loss of SH2B3 in acute lymphoblastic leukemia. Blood. 2013;122:2425\u201332.","journal-title":"Blood"},{"key":"414_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1399-5448.2010.00656.x","volume":"12","author":"EY Lavrikova","year":"2011","unstructured":"Lavrikova EY, Nikitin AG, Kuraeva TL, Peterkova VA, Tsitlidze NM, Chistiakov DA, et al. The carriage of the type 1 diabetes-associated R262W variant of human LNK correlates with increased proliferation of peripheral blood monocytes in diabetic patients. Pediatr Diabetes. 2011;12:127\u201332.","journal-title":"Pediatr Diabetes"},{"issue":"3","key":"414_CR23","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3390\/cancers14030839","volume":"14","author":"D Leardini","year":"2022","unstructured":"Leardini D, Messelodi D, Muratore E, Baccelli F, Bertuccio SN, Anselmi L, et al. Role of CBL mutations in cancer and non-malignant phenotype. Cancers. 2022;14(3):839. https:\/\/doi.org\/10.3390\/cancers14030839.","journal-title":"Cancers"},{"key":"414_CR24","first-page":"3534","volume":"89","author":"CM Niemeyer","year":"1997","unstructured":"Niemeyer CM, Aric\u00f3 M, Basso G, Biondi A, Cant\u00fa Rajnoldi A, Creutzig U, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. Blood. 1997;89:3534\u201343.","journal-title":"Blood"},{"key":"414_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2010-04-280347","volume":"116","author":"JB Oliveira","year":"2010","unstructured":"Oliveira JB, Bleesing JJ, Dianzani U, Fleisher TA, Jaffe ES, Lenardo MJ, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010;116:35\u201340.","journal-title":"Blood"},{"key":"414_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/BOR.0000000000000778","volume":"33","author":"H Li","year":"2021","unstructured":"Li H, Tsokos GC. Double-negative T cells in autoimmune diseases. Curr Opin Rheumatol. 2021;33:163\u201372.","journal-title":"Curr Opin Rheumatol"},{"key":"414_CR27","doi-asserted-by":"publisher","first-page":"5072","DOI":"10.1182\/blood-2010-09-306910","volume":"116","author":"TB Russell","year":"2010","unstructured":"Russell TB, Kurre P. Double-negative T cells are non-ALPS-specific markers of immune dysregulation found in patients with aplastic anemia. Blood. 2010;116:5072\u20133.","journal-title":"Blood"},{"key":"414_CR28","doi-asserted-by":"publisher","first-page":"e0170270","DOI":"10.1371\/journal.pone.0170270","volume":"12","author":"JV Steenholt","year":"2017","unstructured":"Steenholt JV, Nielsen C, Baudewijn L, Staal A, Rasmussen KS, Sabir HJ, et al. The composition of T cell subtypes in duodenal biopsies are altered in coeliac disease patients. PLoS One. 2017;12:e0170270.","journal-title":"PLoS One."},{"key":"414_CR29","doi-asserted-by":"publisher","first-page":"8953","DOI":"10.1073\/pnas.0702975104","volume":"104","author":"JB Oliveira","year":"2007","unstructured":"Oliveira JB, Bid\u00e8re N, Niemela JE, Zheng L, Sakai K, Nix CP, et al. NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci USA. 2007;104:8953\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"414_CR30","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1182\/blood-2010-08-301515","volume":"117","author":"MM Takagi","year":"2011","unstructured":"Takagi MM, Shinoda K, Piao J, Mitsuiki N, Takagi MM, Matsuda K, et al. Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation. Blood Am Soc Hematol. 2011;117:2887\u201390. https:\/\/doi.org\/10.1182\/blood-2010-08-301515.","journal-title":"Blood Am Soc Hematol"},{"key":"414_CR31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","volume":"170","author":"DK Simanshu","year":"2017","unstructured":"Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell Elsevier. 2017;170:17\u201333.","journal-title":"Cell Elsevier"},{"key":"414_CR32","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood-2014-11-567917","volume":"125","author":"KR Calvo","year":"2015","unstructured":"Calvo KR, Price S, Braylan RC, Oliveira JB, Lenardo M, Fleisher TA, et al. JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities. Blood. 2015;125:2753\u20138.","journal-title":"Blood"},{"issue":"1","key":"414_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10875-020-00883-7","volume":"41","author":"Q Neven","year":"2020","unstructured":"Neven Q, Boulanger C, Bruwier A, de Ville M, de Goyet I, Meyts LM, et al. Clinical spectrum of ras-associated autoimmune leukoproliferative disorder (RALD). J Clin Immunol. 2020;41(1):51\u20138. https:\/\/doi.org\/10.1007\/s10875-020-00883-7.","journal-title":"J Clin Immunol"},{"key":"414_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s12016-015-8466-y","volume":"50","author":"P Li","year":"2016","unstructured":"Li P, Huang P, Yang Y, Hao M, Peng H, Li F. Updated understanding of autoimmune lymphoproliferative syndrome (ALPS). Clin Rev Allergy Immunol. 2016;50:55\u201363.","journal-title":"Clin Rev Allergy Immunol"},{"key":"414_CR35","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/bjh.12327","volume":"161","author":"M Koren-Michowitz","year":"2013","unstructured":"Koren-Michowitz M, Gery S, Tabayashi T, Lin D, Alvarez R, Nagler A, et al. SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F. Br J Haematol. 2013;161:811\u201320.","journal-title":"Br J Haematol"},{"key":"414_CR36","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1182\/bloodadvances.2020003754","volume":"5","author":"CE Morales","year":"2021","unstructured":"Morales CE, Stieglitz E, Kogan SC, Loh ML, Braun BS. Nf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia. Blood Adv. 2021;5:3587\u201391.","journal-title":"Blood Adv"},{"key":"414_CR37","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/ng2068","volume":"39","author":"JA Todd","year":"2007","unstructured":"Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet. 2007;39:857\u201364.","journal-title":"Nat Genet"},{"key":"414_CR38","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1084\/jem.20021498","volume":"197","author":"CBF Thien","year":"2003","unstructured":"Thien CBF, Scaife RM, Papadimitriou JM, Murphy MA, Bowtell DDL, Langdon WY. A mouse with a loss-of-function mutation in the c-Cbl TKB domain shows perturbed thymocyte signaling without enhancing the activity of the ZAP-70 tyrosine kinase. J Exp Med. 2003;197:503\u201313.","journal-title":"J Exp Med"},{"key":"414_CR39","doi-asserted-by":"publisher","first-page":"703","DOI":"10.4049\/jimmunol.170.2.703","volume":"170","author":"S Takaki","year":"2003","unstructured":"Takaki S, Tezuka Y, Sauer K, Kubo C, Kwon S-M, Armstead E, et al. Impaired lymphopoiesis and altered B cell subpopulations in mice overexpressing lnk adaptor protein. J Immunol. 2003;170:703\u201310.","journal-title":"J Immunol."},{"key":"414_CR40","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1172\/JCI81468","volume":"126","author":"Y Cheng","year":"2016","unstructured":"Cheng Y, Chikwava K, Wu C, Zhang H, Bhagat A, Pei D, et al. LNK\/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors. J Clin Invest. 2016;126:1267\u201381.","journal-title":"J Clin Invest"},{"key":"414_CR41","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.devcel.2005.03.019","volume":"8","author":"H Ema","year":"2005","unstructured":"Ema H, Sudo K, Seita J, Matsubara A, Morita Y, Osawa M, et al. Quantification of self-renewal capacity in single hematopoietic stem cells from normal and Lnk-deficient mice. Dev Cell. 2005;8:907\u201314.","journal-title":"Dev Cell"},{"key":"414_CR42","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1084\/jem.20011883","volume":"195","author":"L Velazquez","year":"2002","unstructured":"Velazquez L, Cheng AM, Fleming HE, Furlonger C, Vesely S, Bernstein A, et al. Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J Exp Med. 2002;195:1599\u2013611.","journal-title":"J Exp Med"},{"key":"414_CR43","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1182\/blood-2004-10-4093","volume":"105","author":"W Tong","year":"2005","unstructured":"Tong W, Zhang J, Lodish HF. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood. 2005;105:4604\u201312.","journal-title":"Blood"},{"key":"414_CR44","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/pbc.25271","volume":"62","author":"N Hyakuna","year":"2015","unstructured":"Hyakuna N, Muramatsu H, Higa T, Chinen Y, Wang X, Kojima S. Germline mutation of CBL is associated with moyamoya disease in a child with juvenile myelomonocytic leukemia and Noonan syndrome-like disorder. Pediatr Blood Cancer. 2015;62:542\u20134.","journal-title":"Pediatr Blood Cancer"},{"key":"414_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fped.2017.00113","volume":"5","author":"EG Seaby","year":"2017","unstructured":"Seaby EG, Gilbert RD, Andreoletti G, Pengelly RJ, Mercer C, Hunt D, et al. Unexpected findings in a child with atypical hemolytic uremic syndrome: an example of how genomics is changing the clinical diagnostic paradigm. Front Pediatr. 2017;5:1\u20136.","journal-title":"Front Pediatr"},{"issue":"4","key":"414_CR46","doi-asserted-by":"publisher","first-page":"e448","DOI":"10.1212\/NXG.0000000000000448","volume":"6","author":"Y Hong","year":"2020","unstructured":"Hong Y, Keylock A, Jensen B, Jacques TS, Ogunbiyi O, Omoyinmi E, et al. Cerebral arteriopathy associated with heterozygous variants in the casitas B-lineage lymphoma gene. Neurology Genetics. 2020;6(4):e448. https:\/\/doi.org\/10.1212\/NXG.0000000000000448.","journal-title":"Neurology Genetics"},{"key":"414_CR47","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1046\/j.1538-7836.2003.00464.x","volume":"1","author":"JM Auger","year":"2003","unstructured":"Auger JM, Best D, Snell DC, Wilde JI, Watson SP. c-Cbl negatively regulates platelet activation by glycoprotein VI. J Thromb Haemost J Thromb Haemost. 2003;1:2419\u201326.","journal-title":"J Thromb Haemost J Thromb Haemost"},{"key":"414_CR48","unstructured":"Devalli\u00e8 J, Atrice Charreau B. The adaptor Lnk (SH2B3): An emerging regulator in vascular cells and a link between immune and inflammatory signaling."},{"key":"414_CR49","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1042\/BJ20050892","volume":"391","author":"CBF Thien","year":"2005","unstructured":"Thien CBF, Langdon WY. c-Cbl and Cbl-b ubiquitin ligases: Substrate diversity and the negative regulation of signalling responses. Biochem J. 2005;391:153\u201366.","journal-title":"Biochem J"},{"key":"414_CR50","first-page":"904","volume":"460","author":"M Sanada","year":"2009","unstructured":"Sanada M, Suzuki T, Shih LY, Otsu M, Kato M, Yamazaki S, et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nat Publish Group. 2009;460:904\u20138.","journal-title":"Nat Publish Group"},{"key":"414_CR51","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/35003235","volume":"403","author":"YJ Chiang","year":"2000","unstructured":"Chiang YJ, Kole HK, Brown K, Naramura M, Fukuhara S, Hu RJ, et al. Cbl-b regulates the CD28 dependence of T-cell activation. Nature. 2000;403:216\u201320.","journal-title":"Nature"},{"key":"414_CR52","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1101\/gad.297135.117","volume":"31","author":"K Lv","year":"2017","unstructured":"Lv K, Jiang J, Donaghy R, Riling CR, Cheng Y, Chandra V, et al. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies. Genes Dev. 2017;31:1007\u201323.","journal-title":"Genes Dev"}],"container-title":["Human Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-022-00414-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40246-022-00414-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-022-00414-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T15:03:12Z","timestamp":1676818992000},"score":1,"resource":{"primary":{"URL":"https:\/\/humgenomics.biomedcentral.com\/articles\/10.1186\/s40246-022-00414-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,19]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["414"],"URL":"https:\/\/doi.org\/10.1186\/s40246-022-00414-y","relation":{},"ISSN":["1479-7364"],"issn-type":[{"value":"1479-7364","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,19]]},"assertion":[{"value":"9 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}